about
Translocator protein ligands as promising therapeutic tools for anxiety disordersAnxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesisGenetic analysis of dTSPO, an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and Ab42-induced neurodegeneration.Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects.Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971.Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands.Arylthioamides as H2S Donors: l-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in VivoTSPO PIGA Ligands Promote Neurosteroidogenesis and Human Astrocyte Well-BeingPhenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma.Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands.A3 receptor ligands: past, present and future trends.Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands.Medicinal chemistry of indolylglyoxylamide GABAA/BzR high affinity ligands: identification of novel anxiolytic/non sedative agents.Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects.Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection.Residence Time, a New parameter to Predict Neurosteroidogenic Efficacy of Translocator Protein (TSPO) Ligands: the Case Study of N,N-Dialkyl-2-arylindol-3-ylglyoxylamides.Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO).Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance.p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells.Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.Structure-based lead optimization and biological evaluation of BAX direct activators as novel potential anticancer agents.Modulation of PAR(1) signalling by benzimidazole compounds.Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein.Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization.Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands.New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation.Refinement of the benzodiazepine receptor site topology by structure-activity relationships of new N-(heteroarylmethyl)indol-3-ylglyoxylamides.High affinity central benzodiazepine receptor ligands: synthesis and biological evaluation of a series of phenyltriazolobenzotriazindione derivatives.N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor.3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects.Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships.[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives.
P50
Q28249604-18156CC8-B27D-415B-B6F1-08C12E68A77DQ28291960-71610461-0D7E-4721-8E62-202A8C6F7FFDQ33827322-E00D644F-BF71-44A1-B409-A87EB3FA8E70Q34143010-4B2437E6-8E5F-4AD6-99C9-AA1404244BEFQ34365007-C42F741E-2C92-4CFF-9CAA-D8E0B8412501Q34408079-4BACFB7E-7B04-4C2D-917C-62E67322AFE8Q35103479-44331564-3BD4-40D1-A51B-5A540BF98940Q35181925-2E2327B4-9941-468A-8BE0-CEBAC2096E42Q37134394-8F880603-BE2A-4096-821D-22535557AB8FQ37695391-624D6EF3-AEB5-4A51-96ED-77F00A1146A3Q37718142-2D91D384-83FE-4F18-B3E4-C5CE5F2FB51CQ37724971-3C8A6A72-4CCE-46C1-92EB-42D725E1153DQ37724974-013F0D90-5E27-4944-9C47-640FE63B756FQ37835335-FBAE1915-AC0A-4B1B-9B2D-4F13014A7DA4Q37971991-359B7C91-9374-4E18-9A75-E3C18E5D3D15Q37971994-0F7387B4-C805-4723-A258-75AEEAE18685Q38628896-41AF42A1-347B-4D66-88BB-5C2567E34A20Q38688144-9497BEA5-D076-462F-9592-A718B79A14A4Q38693693-231F3F18-5B5D-4FD5-87D7-7D38EC3CB329Q38839883-EA7B5200-5ECC-4547-AC4E-36D55C98E58FQ38938735-2E18CDB8-B2D6-4A27-92B8-538ECFF3E1ABQ39013934-43CC42E2-4417-487A-B064-A5CF5E68FFA8Q39020023-080CFAAE-37A9-4A2E-B90F-E5498B2EF4F4Q39032395-D98D8590-D099-479E-AD8F-2AC04034146DQ39041318-23C80701-3402-4098-9E46-998949027C08Q39361791-24F22AC3-A592-4212-A77B-79D92AD1BF7FQ39366925-AFD0BAE9-501A-4D39-B09A-2B0BAEE29407Q39493323-2AE376BD-BE61-4186-8B4A-C9B7D3063F21Q39708231-98805721-E881-4E09-A6BF-2DCDF101538FQ39712416-6EF06FEB-AD60-45A1-8DF5-01A019383EFDQ40163832-00A77FDB-9141-4C2F-94A2-FC020CEF3B0CQ40182400-2C7379EB-7E5D-4D91-AC3D-3EC23C49B340Q40293381-DBB1A479-FFEC-4CE6-89E2-0407E7FC2AD7Q40435715-ADEA5371-3FC5-40C6-BE9A-C2DA265CCAEEQ40577336-5CCBF2CF-1B43-4DD0-8C65-0E8EE3F3B4C8Q40696312-FD5D8EE2-8A47-48E2-9E32-2082DE285E03Q42513564-905067E4-D4F5-4F0D-9EE4-83C51E62A543Q43655332-143A2474-52F0-4154-979F-E2C7186BB184Q43812034-9AF26D06-5ED3-4949-80F9-90DA4369FE05Q44283724-1E57E270-1D5C-4109-B820-80DBE5CC4D3C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sabrina Taliani
@ast
Sabrina Taliani
@en
Sabrina Taliani
@es
Sabrina Taliani
@nl
type
label
Sabrina Taliani
@ast
Sabrina Taliani
@en
Sabrina Taliani
@es
Sabrina Taliani
@nl
altLabel
S Taliani
@en
SABRINA TALIANI
@en
prefLabel
Sabrina Taliani
@ast
Sabrina Taliani
@en
Sabrina Taliani
@es
Sabrina Taliani
@nl
P106
P1153
6602340116
P21
P31
P496
0000-0001-8675-939X